Gibbs International Research Institute Welcomes New Chief Operating Officer
Pathologist and Pharmaceutical Research Executive Mark Watson, M.D., Ph.D. has joined the executive team of Gibbs International Research Institute (GIRI) as its Chief Operating Officer.
A graduate of Duke University Medical Center and the University of Texas at Southwestern Medical Center in Dallas, Texas, Dr. Watson has extensive experience with developing Drug-Companion Diagnostic products in large pharmaceutical companies including Glaxo-SmithKline, Merck and Schering-Plough where he served to integrate phamacogenomic biomarkers into clinical trials. The biomarkers identify genetic differences that can affect individual responses to medications, both in terms of therapeutic effect as well as adverse effects.
“Mark’s experience in developing personalized medicines, integrating genetics into clinical trials, and leading cutting-edge clinical research will provide tremendous value as he helps develop and execute the GIRI's initiative in personalized cancer care – finding the right medications for the right patients at the right time,” said Timothy Yeatman, M.D., Director and President of Gibbs Cancer Center and Research Institute. “Research drives reputation for both the Gibbs and Spartanburg Regional Healthcare System, so we are excited to have another talented individual leading these efforts to make research and superior patient care a priority here in the Upstate.”
GIRI is the newest expansion of the Gibbs Cancer Research Institute. GIRI’s focus is to bring the best new medicines in cutting-edge clinical trials to the community, and revolutionize the way cancer clinical trials are performed.